DE69019141D1 - Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie. - Google Patents

Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.

Info

Publication number
DE69019141D1
DE69019141D1 DE69019141T DE69019141T DE69019141D1 DE 69019141 D1 DE69019141 D1 DE 69019141D1 DE 69019141 T DE69019141 T DE 69019141T DE 69019141 T DE69019141 T DE 69019141T DE 69019141 D1 DE69019141 D1 DE 69019141D1
Authority
DE
Germany
Prior art keywords
composition
preferably comprises
prostate hypertrophy
treating
treating good
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69019141T
Other languages
English (en)
Other versions
DE69019141T2 (de
Inventor
Muharrem Gokcen
Terry Guy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunolytics Inc
Original Assignee
Immunolytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunolytics Inc filed Critical Immunolytics Inc
Publication of DE69019141D1 publication Critical patent/DE69019141D1/de
Application granted granted Critical
Publication of DE69019141T2 publication Critical patent/DE69019141T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
DE69019141T 1989-01-27 1990-01-19 Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie. Expired - Fee Related DE69019141T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30380989A 1989-01-27 1989-01-27
US42996689A 1989-10-31 1989-10-31
PCT/US1990/000423 WO1990008555A1 (en) 1989-01-27 1990-01-19 Composition and method for treating benign prostatic hypertrophy

Publications (2)

Publication Number Publication Date
DE69019141D1 true DE69019141D1 (de) 1995-06-08
DE69019141T2 DE69019141T2 (de) 1996-01-18

Family

ID=26973659

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69019141T Expired - Fee Related DE69019141T2 (de) 1989-01-27 1990-01-19 Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.

Country Status (10)

Country Link
US (1) US6296847B1 (de)
EP (1) EP0456724B1 (de)
JP (1) JP3054190B2 (de)
AT (1) ATE121946T1 (de)
AU (1) AU5045690A (de)
DE (1) DE69019141T2 (de)
DK (1) DK0456724T3 (de)
ES (1) ES2072424T3 (de)
HK (1) HK1003981A1 (de)
WO (1) WO1990008555A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305460C2 (de) * 1993-02-23 1997-09-04 Albert Dr Scheller Pharmazeutische oder kosmetische, Enzyme enthaltende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
US7018365B2 (en) 1999-05-21 2006-03-28 Micro Therapeutics, Inc. Threaded syringe with quick stop
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
DE60034694T2 (de) * 1999-09-24 2008-01-17 Proteon Therapeutics, Inc. Verwendung von elastase zur öffnung verstopfter arterien und venen
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
US6428785B1 (en) * 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US6678391B2 (en) * 2000-04-18 2004-01-13 Matsushita Electric Industrial Co., Ltd. Organism-specimen morphological-change detecting apparatus, and organism-specimen morphological-change detecting method
WO2002074329A1 (en) * 2001-03-19 2002-09-26 Ribeiro Santana Cristiano Albe Pharmaceutical composition applied to the treatment of the peyronie disease and corresponding obtention process
EP1471935A2 (de) * 2002-02-06 2004-11-03 N-Zyme BioTec GmbH Protease-screening und neue verwendung von proteasen
US7807618B2 (en) * 2002-05-20 2010-10-05 The Board Of Regents Of The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone and other tissues
WO2004026335A1 (en) * 2002-09-19 2004-04-01 Santana Cristiano Alberto Ribe Pharmaceutical composition comprising carriers for products
US7437194B2 (en) * 2003-10-31 2008-10-14 Medtronic, Inc. Stimulating the prostate gland
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
KR20070116710A (ko) 2005-03-03 2007-12-11 알러간, 인코포레이티드 보툴리눔 독소를 정제하기 위한 동물 산물이 없는 시스템및 프로세스
KR101447184B1 (ko) * 2006-11-10 2014-10-08 엘아이지에이디피 주식회사 게이트슬릿 개폐장치가 구비된 공정챔버
EP2117584B1 (de) * 2007-02-15 2013-10-09 Allergan, Inc. Verwendung von botulinumtoxin und enzymen zur behandlung von blasenleiden
AT506095A1 (de) * 2007-12-03 2009-06-15 Volopharm Gmbh Verwendung von proteasen
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
ES2690568T3 (es) 2011-07-20 2018-11-21 Mediwound, Ltd. Extracto proteolítico de bromelaína para el tratamiento de trastornos del tejido conectivo
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
RU2647783C2 (ru) 2012-08-10 2018-03-19 Осио Корпорейшн Д/Б/А Иолиа Хелт Использование контактных линз при лечении офтальмологического нарушения
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3792161A (en) 1970-05-18 1974-02-12 Research Corp Burn ointment comprising silver sulfadiazine and collagenase
US3678158A (en) 1971-05-11 1972-07-18 Worthington Bio Chem Corp Treatment of herniated intervertebral discs of mammals
US4276284A (en) 1971-07-26 1981-06-30 Brown Stuart I Prevention of collagenase induced disease by treatment with collagenase inhibitors
US3977408A (en) 1974-11-01 1976-08-31 Mackew Allan H Prosthetic catheter
US4005194A (en) 1975-06-23 1977-01-25 Abbott Laboratories Treatment of prostatic hyperplasia
US4317818A (en) 1976-05-10 1982-03-02 Richardson-Merrell Inc. Method of treating prostatic carcinoma
DE2655801C2 (de) 1976-12-09 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
US4174389A (en) 1977-05-13 1979-11-13 Cope Louise A Ophthalmic use of collagenase
CH624011A5 (de) 1977-08-05 1981-07-15 Battelle Memorial Institute
DE2817157A1 (de) 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4329430A (en) * 1979-06-04 1982-05-11 Klein Gerold K V Enzyme mixture
US4317817A (en) 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
US4276281A (en) 1980-09-04 1981-06-30 Crikelair George F Burn treatment
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS58189122A (ja) 1982-04-30 1983-11-04 Kaken Pharmaceut Co Ltd 高脂血症予防治療剤
JPS5951221A (ja) 1982-09-17 1984-03-24 Eisai Co Ltd 変形性関節症治療剤
IT1189379B (it) * 1982-10-08 1988-02-04 Serono Ist Farm Composizione farmaceutica contenente un agente fibrinolitico ed un fattore di diffusione,utile per il trattamento dell'infarto miocardico
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4678668A (en) * 1985-10-28 1987-07-07 Md Associates Method of reducing soft tissue swelling and pain
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy

Also Published As

Publication number Publication date
ES2072424T3 (es) 1995-07-16
EP0456724A1 (de) 1991-11-21
US6296847B1 (en) 2001-10-02
ATE121946T1 (de) 1995-05-15
JPH04503071A (ja) 1992-06-04
HK1003981A1 (en) 1998-11-13
EP0456724B1 (de) 1995-05-03
JP3054190B2 (ja) 2000-06-19
DE69019141T2 (de) 1996-01-18
WO1990008555A1 (en) 1990-08-09
AU5045690A (en) 1990-08-24
DK0456724T3 (da) 1995-10-02

Similar Documents

Publication Publication Date Title
DE69019141D1 (de) Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.
ATE373483T1 (de) Zusammensetzung zur behandlung von prostatakrebs
PT1238141E (pt) Fibras de sementes de plantas e seu uso
DK1140078T3 (da) Vaskulærskadende benzimidazolmidler
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
DE69908156D1 (de) Arylsulfonanilid-harnstoffe
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
SE0001914L (sv) Förbättring av Peyronies sjukdom
ES2174921T3 (es) Inhibidores de la proteasa del vih.
ES2148312T3 (es) Inhibidores selectivos de aromatasa.
ES511604A0 (es) "un procedimiento para la obtencion de un principio activo fibrinolitico vasal o vascular, quimicamente denominable "enzima angioquinasa"".
IT1270993B (it) Derivati chinzolilamminici attivi come alfa-antagonisti
Polakoski et al. An acrosin-acrosin inhibitor complex in ejaculated boar sperm
Singer et al. Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
EP0817645A4 (de) Verfahren zur behandlung der gestartigen hypertrophie der prastate
PT1194109E (pt) Formulacoes topicas compreendendo agentes de penetracao na pele e utilizacao dasmesmas
ATE248845T1 (de) Arylsulfonanilid-phosphate
PT793666E (pt) Processo de sililacao
ES2105289T3 (es) Disolucion de poliimida y su procedimiento de obtencion.
ES2084657T3 (es) Agente para el tratamiento de los trastornos del sistema de transmision cerebro-neural.
ATE221068T1 (de) Anellierte beta-carboline
NZ331374A (en) Phenanthridine compounds and pharmaceutical compositions thereof
CO4790092A1 (es) Granisetron para tratamiento de la diarrea

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee